EVOPEDIA

← all systems · see it in The System

Receptor-ligand binding

In biochemistry and pharmacology, receptors are proteins that receive and transduce signals that may be integrated into biological systems. In protein-ligand binding, the ligand is usually a molecule which produces a signal by binding to a site on a target protein.

Properties published scienceour proposal

Sourced fields, and our own readings.

born atwith the first cells (rung 6); not dated in the sources read
born precisionnot given
boundaryInside: one ligand and one receptor's binding site from encounter to release, the receptor's conformational change and its coupling to an effector, and the regulation of the receptor's sensitivity; the measures the field uses (Kd, kon, koff, residence time, efficacy). Outside: the downstream signalling cascades, the cell's decisions, the body's pharmacokinetics (how the drug reaches the tissue) and the chemistry that makes the ligand.
nested levelA molecular event inside the receptor floor of a cell (the cell's L2) and inside the binding pocket of a protein; built from a ligand, a receptor protein's site and the water between them; embedded in membranes, clefts and cytoplasm; carries pharmacology and drug discovery.
scalemolecular

Measures (23) published science

Dissociation constantKd = koff/kon (the same Kd from fast-on fast-off or slow-on slow-off) M
Association rate constant (kon), basal10^5 to 10^6 per molar per second
Association rate constant (kon), electrostatically assisted10^8 to 10^9 per molar per second
Association rate ceiling used for drug-target encounter10^9 per molar per second
Residence time of a drug-target complextR = 1/koff s
Minimum residence time at a given affinityat least 12 min at Kd 1 pM; at least 11.5 days at Kd 1 fM time
Tiotropium dissociation half-time (M3 receptor)462 (Kd 10 pM, koff 0.0015 per min)
Time to equilibrium97% of equilibrium after 5 half-times; about 10-fold faster at 90% than at 10% occupancy; tiotropium 3.5 h at 100 pM, 35 h at 0.3 pM
Occupancy giving a maximal response (spare receptors)<1 % of receptors
Maximal binding free energy per heavy atomabout -1.5 kcal/mol per atom, flattening above about 15 heavy atoms
Enthalpy gained and entropy lost by one added hydrogen bond (HIV-1 protease inhibitor)3.9 kcal/mol each way, net affinity unchanged
Ligand-gated channel openingrise within a microsecond; open for milliseconds
Haemoglobin quaternary transitionabout 2 microseconds
Short-term desensitisationminutes time
Downregulationhours to days; beta2 receptor binding sites down 50-60% after prolonged agonist time
Members of the GPCR family (review)approximately 800 genes
Members of the GPCR family (encyclopedia)at least 810 members
Approved drugs acting at GPCRs475 drugs at 108 GPCRs, about 34% of FDA-approved drugs (abstract); 481 drugs at 107 GPCR targets (body text)
Receptor tyrosine kinases20 classes, 58 receptors
Clark's acetylcholine uptake estimate against later measurementsabout 1000 times too high ratio
Rebinding factor used in simulations3 to 100 (kon x [Rtot]/k) dimensionless
Acetylcholine-binding sites on a nicotinic receptor2-5 sites
Rise of the GPCR response after agonist bindingwithin seconds; peaks within a few milliseconds to a few minutes depending on the receptor, then declines while the complex persists time

Open contentions (7) open contention

Where sources or readings disagree. Both stay on the map.

Cross-scale patterns seen here (17) our proposal

Shapes that recur when the same kind of problem is solved at different scales, and how each shows in Receptor-ligand binding. Each links to every other system that shows it.

Valence: what it trades, and with whom (16) published science

Each exchange with a neighbour, read from both sides: who gains, who pays, and what carries it.

Partners and parts published science

Built from / builds (5)

Sits inside / holds (4)

expressed by (8)

floor filled by (19)

represents (1)

Kinds (13)

Notes published science

Layers

The ways it takes in its world, where they meet, and how it acts back, each from L1 (where it meets the world) up.

binding thermodynamics: water, heat and free energy at the site

  1. L1: Water around the empty site and around the ligand: hydrogen-bonded networks in the pocket and hydration shells on the ligand
  2. L2: Desolvation: water leaves the pocket and the ligand's surface; its enthalpy or entropy can drive binding or rejection; the classical released-water picture of the hydrophobic effect fits few real cases
  3. L3: The balance: dG = dH - TdS; tighter contacts cost freedom; enthalpy and entropy often compensate so affinity does not move; measured directly by isothermal titration calorimetry
  4. L4: Affinity as read out: the Kd; at most about 1.5 kcal/mol per heavy atom for the strongest binders, flattening past about 15 heavy atoms

receptor evolution: genes, duplication and new ligand pairs

  1. L1: Receptor genes: the first steroid receptor bound estrogen, then a progesterone receptor
  2. L2: Duplication: the full set of mammalian steroid receptors from two large-scale genome expansions
  3. L3: Latent affinity: the ancestral receptor already bound aldosterone as a by-product of binding older, similar ligands
  4. L4: Specificity tuned: two amino acid changes recreate today's specificity
  5. L5: New hormone-receptor pairs and an integrated system; orphan receptors whose ligands may sit among related synthesis intermediates

receptor-ligand binding as pharmacologists and biophysicists describe it: from ligand in solution to the response (reader's view)

  1. L1: The ligand free in the solution at the receptor: a transmitter, hormone, drug, toxin, ion or part of a microbe, at a concentration; binding itself drains the free pool (ligand depletion)
  2. L2: Encounter and association: diffusion to the site through a transient complex; kon about 10^5-10^6 per molar per second with no helping force, 10^8-10^9 with complementary charges; reversible by dissociation (koff); measured in real time by surface plasmon resonance
  3. L3: The bound complex: a site of complementary shape held by ionic bonds, hydrogen bonds, van der Waals forces and the hydrophobic effect, with water rearranged; affinity (Kd = koff/kon), occupancy and residence time (1/koff); saturable and finite. Three quantities on different footings: Kd an equilibrium constant, occupancy a concentration-dependent state, residence time a lifetime. For an agonist the Kd an experiment returns mixes binding with activation (contention C-3902); the number also depends on the method and conditions
  4. L4: The receptor's conformation: resting R and active R* (and desensitised states) in equilibrium; an agonist prefers R*, an antagonist neither, an inverse agonist R; efficacy; constitutive activity; allosteric coupling between sites (alpha); whether the ligand selects or induces the active shape is argued. Written here in two-state terms; whether there are two states or a landscape of many is argued (contention C-3994), as is whether the ligand selects or induces the active shape (C-3950)
  5. L5: Coupling to the effector: the channel opens (ionotropic), a G protein exchanges GDP for GTP (metabotropic), a kinase domain works (enzyme-linked), or the receptor carries itself to DNA (nuclear); relay, amplification or integration; with spare receptors a maximal response comes at low occupancy; the same recognise-and-switch architecture runs in RNA alone (riboswitches)
  6. L6: Regulation of the response: desensitisation over minutes (GRK phosphorylation, beta-arrestins), downregulation over hours to days (internalisation, degradation), up- and downregulation of receptor number; bias towards one pathway (ligand, receptor or system bias); allosteric modulators
  7. L7: What the cell and body do: a change in a cell's electrical activity, muscle contraction, secretion, gene expression; for a person, a hormone's effect, a sense, a drug's action or a poison's

the boardroom (shared floors)

  1. L3: The bound complex: affinity, occupancy and residence time; the site where ligand, competitors, water, heat and the tissue's geometry meet
  2. L4: The receptor's conformational equilibrium: R, R*, desensitised states; efficacy; allosteric coupling
  3. L5: Coupling to the effector: channel gating, G protein exchange, kinase activity, DNA binding; relay, amplification, integration
  4. L6: Regulation of sensitivity and pathway: desensitisation, downregulation, bias
  5. L7: The response of the cell and body

way in: Allosteric modulators (ligands at a second site)

  1. L1: A modulator in solution (e.g. a benzodiazepine; a pathway's end product for an enzyme)
  2. L2: Binding at a site distinct from the orthosteric one
  3. L3: The cooperativity factor alpha: raises or lowers the other ligand's affinity (and may change its efficacy)

way in: Covalent marks written on the receptor (GRK phosphorylation, ubiquitin)

  1. L1: Kinases in the cytoplasm (GPCR kinases)
  2. L2: The agonist-occupied receptor phosphorylated
  3. L3: Beta-arrestin recruited
  4. L4: G protein kept off the receptor
  5. L5: Ubiquitin marks for degradation; internalisation

way in: Heat (temperature)

  1. L1: Temperature of the solution and tissue
  2. L2: Temperature shifts Kd (van 't Hoff) and the off-rate

way in: Other ligands at the same site (antagonists, partial agonists, rival endogenous ligands)

  1. L1: A second ligand in the same solution
  2. L2: Mutually exclusive occupancy of one site: the agonist curve shifts in parallel (Schild's dose ratio)

way in: The ligand itself (agonist or endogenous ligand)

  1. L1: Free ligand at a concentration in the extracellular fluid, the cleft or the cytoplasm
  2. L2: Diffusion and encounter: the transient complex; the on-rate

way in: The membrane and tissue around the receptor (confinement, density, rebinding)

  1. L1: Receptors in membranes, often densely, facing clefts and walls
  2. L2: Hindered diffusion: effective on- and off-rates are both divided by (1 + kon[R]/k), so freed ligand rebinds before drifting away; receptors are not evenly spread (rafts, microdomains), which changes local density

way in: The receptor's own make and number (genes, mutations, expression)

  1. L1: The receptor's sequence; mutations
  2. L2: How many receptors the cell holds (up- and downregulation)
  3. L3: The unliganded R to R* balance: constitutive activity

way in: The transducer bound on the inside (G protein, arrestin)

  1. L1: G protein heterotrimers on the inner face (alpha with GDP, beta, gamma)
  2. L2: The G protein docks on the active receptor: the ternary complex
  3. L3: Coupling changes ligand affinity: an inverse agonist's affinity rises when the G protein is uncoupled

way in: Water (the solvent in the pocket and around the ligand)

  1. L1: The hydrogen-bond network of the solvent
  2. L2: Water in the pocket and on the ligand rearranged or displaced

way out: Enzyme activity (enzyme-linked receptors)

  1. L1: Proteins in the cytoplasm modified
  2. L5: An intracellular enzymatic domain, linked through one membrane helix

way out: G protein and second messengers (metabotropic)

  1. L1: Effector enzymes and second messengers in the cytoplasm
  2. L5: GDP exchanged for GTP; alpha leaves beta-gamma

way out: Gene expression (nuclear receptors)

  1. L1: Zinc fingers read DNA sequences
  2. L5: The liganded receptor moves to the nucleus

way out: Ion flow (ligand-gated channels)

  1. L1: Ions cross the membrane down their gradient
  2. L5: At the nicotinic acetylcholine receptor studied by the source: the channel opens all-or-none; open time varies with the agonist, the unitary conductance does not (a per-receptor finding)

way out: Receptor removal (internalisation and degradation)

  1. L1: Fewer receptors in the membrane
  2. L5: Receptors taken into vesicles
  3. L6: Downregulation over hours to days

way out: Release of the ligand back into the solution (dissociation, rebinding)

  1. L1: Back in the free pool
  2. L2: Freed ligand may rebind the same or nearby receptors first
  3. L3: The complex falls apart at koff; residence time 1/koff

Sources (30) published science

Ligand (biochemistry), rev 1378341588 (Wikipedia, via Wikimedia Enterprise snapshot 2026-11-01)
Rajagopal S, Shenoy SK 2018, GPCR desensitization: acute and prolonged phases. Cell Signal 41:9-16. doi:10.1016/j.cellsig.2017.01.024 (PMC5533627); sections read (specialist phase): abstract, introduction, GPCR phosphorylation, proteins that affect desensitization (behind its links)
Receptor (biochemistry), rev 1378338616 (Wikipedia, via Wikimedia Enterprise snapshot 2026-11-01) (behind its links)
Costa T, Herz A 1989, Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. PNAS 86:7321-7325. doi:10.1073/pnas.86.19.7321 (PMC298053) (behind its links)
Vauquelin G 2016, Effects of target binding kinetics on in vivo drug efficacy: koff, kon and rebinding. Br J Pharmacol 173:2319-2334. doi:10.1111/bph.13504 (PMC4945762); sections read: abstract, introduction, rebinding equations, discussion (behind its links)
Hill equation (biochemistry) (Wikipedia, via Wikimedia Enterprise snapshot 2026-11-01) (behind its links)
Allosteric regulation (encyclopedia; Wikimedia Enterprise snapshot 2026-11-01) (behind its links)
McKeithan TW 1995, Kinetic proofreading in T-cell receptor signal transduction. PNAS 92:5042-5046. doi:10.1073/pnas.92.11.5042 (PMC41844) (behind its links)
Thornton JW 2001, Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. PNAS 98:5671-5676. doi:10.1073/pnas.091553298 (PMC33271) (behind its links)
Receptor theory, rev 1310485821 (Wikipedia, via Wikimedia Enterprise snapshot 2026-11-01) (behind its links)
Dissociation constant (Wikipedia, via Wikimedia Enterprise snapshot 2026-11-01) (behind its links)
Schreiber G, Haran G, Zhou HX 2009, Fundamental aspects of protein-protein association kinetics. Chem Rev 109:839-860. doi:10.1021/cr800373w (PMC2880639); sections read: introduction (the transient complex, basal and enhanced rate constants) (behind its links)
Tonge PJ 2018, Drug-target kinetics in drug discovery. ACS Chem Neurosci 9:29-39. doi:10.1021/acschemneuro.7b00185 (PMC5767540); sections read: abstract, binding kinetics and residence time, kinetic selectivity, target vulnerability (behind its links)
Hulme EC, Trevethick MA 2010, Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161:1219-1237. doi:10.1111/j.1476-5381.2009.00604.x (PMC3000649); sections read: abstract, introduction, kinetics of equilibration, radioligand depletion, temperature (behind its links)
Kuntz ID, Chen K, Sharp KA, Kollman PA 1999, The maximal affinity of ligands. PNAS 96:9997-10002. doi:10.1073/pnas.96.18.9997 (PMC17830) (behind its links)
Fox JM, Zhao M, Fink MJ, Kang K, Whitesides GM 2018, The molecular origin of enthalpy/entropy compensation in biomolecular recognition. Annu Rev Biophys 47:223-250. doi:10.1146/annurev-biophys-070816-033743; sections read: introduction, general sources, hydrogen bonds, water and the hydrophobic effect, why study H/S compensation (behind its links)
Changeux JP, Edelstein S 2011, Conformational selection or induced fit? 50 years of debate resolved. F1000 Biol Rep 3:19. doi:10.3410/b3-19 (PMC3169905); sections read: abstract, introduction, thermodynamics and kinetics, methods, haemoglobin, aspartate transcarbamoylase, nicotinic acetylcholine receptor (behind its links)
Smith EI et al. 2018. Humans thrived in South Africa through the Toba eruption about 74,000 years ago. Nature 555:511-515. doi:10.1038/nature25967 (behind its links)
Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE 2017, Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16:829-842. doi:10.1038/nrd.2017.178 (PMC6882681); sections read: abstract, introduction, established and novel targets (behind its links)
Rang HP 2006, The receptor concept: pharmacology's big idea. Br J Pharmacol 147 Suppl 1:S9-16. doi:10.1038/sj.bjp.0706457 (PMC1760743) (behind its links)
Bridgham JT, Carroll SM, Thornton JW 2006, Evolution of hormone-receptor complexity by molecular exploitation. Science 312:97-101. doi:10.1126/science.1123348 (behind its links)
Receptor antagonist (Wikipedia, via Wikimedia Enterprise snapshot 2026-11-01) (behind its links)
Hopfield 1974. Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. PNAS 71:4135-4139. doi:10.1073/pnas.71.10.4135 (PMC434344) (behind its links)
Baron R, Setny P, McCammon JA 2010, Water in cavity-ligand recognition. J Am Chem Soc 132:12091-12097. doi:10.1021/ja1050082 (PMC2933114) (behind its links)
Colquhoun D 1998, Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947. doi:10.1038/sj.bjp.0702164 (PMC1565672); sections read: abstract, the nature of the problem, del Castillo-Katz, the ternary complex cube (behind its links)
Zhou HX 2010, From induced fit to conformational selection: a continuum of binding mechanism controlled by the timescale of conformational transitions. Biophys J 98(6):L15-L17. doi:10.1016/j.bpj.2009.11.029 (PMC2849054); a three-page letter, read whole (behind its links)
Breaker RR 2012. Riboswitches and the RNA world. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a003566 (behind its links)
Copeland, Sami, Tsujikawa, Dynamics of dark energy, arXiv:hep-th/0603057 (sections I-IV read) (behind its links)
Copeland RA 2016, The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov 15:87-95. doi:10.1038/nrd.2015.18 (behind its links)
Dahl G, Akerud T 2013, Pharmacokinetics and the drug-target residence time concept. Drug Discov Today 18:697-707. doi:10.1016/j.drudis.2013.02.010 (behind its links)